Quick - Wegovy Semaglutide Weight Loss | NAD iv Therapy Georgia

Quick operates as a specialized medical weight loss and cellular wellness clinic serving patients throughout Georgia from its Atlanta base, focusing exclusively on semaglutide weight management protocols and NAD+ intravenous therapy under the clinical oversight of OnGo Care. The clinic addresses the growing demand for medically supervised weight loss and metabolic optimization through evidence-based pharmacotherapy and cellular restoration treatments, providing both telehealth consultations and in-person administration services across the state.

The clinic's weight management program centers on Wegovy (semaglutide 2.4mg), the FDA-approved GLP-1 receptor agonist indicated for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. Quick's semaglutide protocols include comprehensive metabolic assessment, dose titration schedules that minimize gastrointestinal side effects, and ongoing monitoring of weight loss progression and cardiovascular risk factors. The program incorporates nutritional guidance aligned with reduced appetite signaling and addresses common challenges such as medication adherence, plateau management, and transition strategies for long-term weight maintenance. For cellular wellness, Quick administers NAD+ (nicotinamide adenine dinucleotide) intravenous therapy in doses typically ranging from 250mg to 1000mg per session, targeting mitochondrial function, cellular energy production, and metabolic efficiency that often declines with age or metabolic dysfunction.

OnGo Care provides clinical oversight for Quick's treatment protocols, ensuring appropriate patient selection through screening for contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and pancreatitis history for semaglutide candidates. The provider network conducts baseline laboratory assessments including lipid panels, hemoglobin A1c, thyroid function, and liver enzymes before initiating weight loss therapy, with follow-up testing at regular intervals to document metabolic improvements. For NAD+ therapy, providers evaluate patients for conditions that may benefit from cellular energy support, including chronic fatigue, metabolic syndrome, and age-related cognitive changes, while monitoring infusion tolerance and adjusting administration rates to minimize flushing or discomfort that can occur with rapid NAD+ delivery.

Patients beginning treatment at Quick in Atlanta typically start with a telehealth consultation for medical history review, treatment goal discussion, and eligibility determination, followed by in-person visits for medication pickup or NAD+ infusion administration at the clinic's Georgia location. Semaglutide patients receive weekly subcutaneous injections that they self-administer at home following initial training, with dose escalation occurring monthly over 16-20 weeks to reach the maintenance dose of 2.4mg weekly. NAD+ infusion sessions last approximately 2-4 hours depending on dose and individual tolerance, with many patients scheduling weekly or biweekly treatments initially before transitioning to monthly maintenance protocols. The clinic provides ongoing access to clinical support through telehealth check-ins, addressing questions about side effect management, dose adjustments, and treatment optimization throughout the care continuum.

Quick's hybrid telehealth and in-person model addresses geographic barriers for Georgia patients seeking specialized metabolic and cellular wellness treatments, eliminating the need for repeated travel to Atlanta for routine consultations while maintaining in-person touchpoints for medication dispensing and intravenous therapy administration. The clinic's focused treatment menu allows for streamlined care pathways and specialized expertise in semaglutide weight management and NAD+ therapy rather than diluted attention across dozens of treatment modalities. This specialization enables Quick to maintain current knowledge of emerging research on GLP-1 agonist applications beyond weight loss, including cardiovascular and renal protective effects, and evolving protocols for NAD+ administration in metabolic and longevity medicine.